Cargando…
Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
Activating mutations in Kirsten rat sarcoma viral oncogene homologue (KRAS), in particular, a point mutation leading to a glycine-to-cysteine substitution at codon 12 (G12C), are among the most frequent genomic alterations in non-small cell lung cancer (NSCLC). Several agents targeting KRAS G12C hav...
Autores principales: | Cheema, Parneet K., Banerji, Shantanu O., Blais, Normand, Chu, Quincy S.-C., Juergens, Rosalyn A., Leighl, Natasha B., Sacher, Adrian, Sheffield, Brandon S., Snow, Stephanie, Vincent, Mark, Wheatley-Price, Paul F., Yip, Stephen, Melosky, Barbara L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377814/ https://www.ncbi.nlm.nih.gov/pubmed/37504336 http://dx.doi.org/10.3390/curroncol30070476 |
Ejemplares similares
-
Canadian Consensus Recommendations on the Management of MET-Altered NSCLC
por: Cheema, Parneet K., et al.
Publicado: (2021) -
Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer
por: Melosky, Barbara L., et al.
Publicado: (2023) -
Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
por: Rupp, Martin, et al.
Publicado: (2023) -
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults †
por: Bebb, D. Gwyn, et al.
Publicado: (2021) -
The dawn of a new era, adjuvant EGFR inhibition in resected non-small
cell lung cancer
por: Melosky, Barbara, et al.
Publicado: (2021)